Browsing Tag
ATAI Life Sciences
5 posts
atai Beckley emerges as new global leader after atai Life Sciences and Beckley Psytech complete strategic merger in mental-health biotech
Find out how atai Life Sciences and Beckley Psytech’s merger to form atai Beckley is reshaping psychedelic biotech and transforming depression treatment.
Atai Life Sciences stock jumps 15% after Beckley Psytech trial update deepens investor interest in BPL-003
Atai Life Sciences stock surged 15% after positive BPL-003 trial data with Beckley Psytech. Investors eye Phase 3 momentum and merger milestones.
Who’s funding the psychedelic revolution in pharma? Follow the money from PIPEs to Big Pharma M&A
Psychedelic biotech is evolving—from VC hype to pharma buyouts. Discover who’s funding the next generation of depression treatments in 2025.
Atai Life Sciences acquires exclusive rights to Psilera’s DMT patent portfolio
Atai Life Sciences has taken a strategic step in expanding its position in psychedelic medicine by securing exclusive…
ATAI Life Sciences partners with Neuronasal to develop concussion treatment
ATAI Life Sciences, a German biotech company focused on developing drugs for mental illnesses, has partnered with Neuronasal…